December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vanguard Health Care ETF (NY:VHT)

291.86 +1.96 (+0.68%)
Streaming Delayed Price Updated: 12:34 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vanguard Health Care ETF

< Previous 1 2 3 4 Next >
News headline image
Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone ↗
Baird analyst Catherine Ramsey Schulte slashed the price target on Grail to $82 from $113 while reiterating an ‘Outperform’ rating. 
Via Stocktwits
News headline image
MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event ↗
Some Stocktwits users voiced optimism for the inflammation-drug maker getting acquired by pharma giant Merck. 
Via Stocktwits
Topics Intellectual Property
News headline image
IBRX Stock Jumps 6% Pre-Market On BCG Update In Saudi Arabia – Retail Says Share Price Is ‘Attractive’ ↗
The Saudi Food and Drug Authority encouraged the company to submit a regulatory filing for its recombinant Bacillus Calmette-Guérin, which the company expects to submit within weeks. 
Via Stocktwits
News headline image
Why Did INTS Stock Plummet 30% Pre-Market Today? ↗
Intensity Therapeutics announced a 1-for-25 reverse stock split, consolidating every 25 existing shares into a single new share. 
Via Stocktwits
Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb ↗
Via Stocktwits
BDSX Stock Shot Up 23% Pre-Market Today — What’s Fueling The Surge? ↗
Via Stocktwits
Why Is Tempus AI Stock Surging 11% Premarket Today? ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results ↗
Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin. 
Via Stocktwits
News headline image
HUMA Stock Just Shot Up 12% Today – Here’s Everything To Know About The DOD Funding Fueling The Surge ↗
The company stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration. 
Via Stocktwits
News headline image
Why Did Healthcare Triangle Stock Plummet 20% Today? ↗
The technology firm announced that it will implement a 1-for-60 reverse stock split of its common shares effective at 12:01 a.m. Eastern Time on February 10. 
Via Stocktwits
News headline image
MDXG Stock Rises As MiMedx Enters Into Exclusive Distribution Agreement For Three Products ↗
According to the agreement, Summit Products Group will distribute Hydrelix, NovaForm, and G4Derm Plus, designed to complement MiMedx’s portfolio of leading surgical and wound products. 
Via Stocktwits
Topics Artificial Intelligence
MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations ↗
Via Stocktwits
SNDX Stock Is The Talk Of The Town Today: Here’s Everything To Know About The Latest FDA Approval ↗
Via Stocktwits
News headline image
Why Did GUTS Stock Plummet Today Despite Positive Gut Therapy Midterm Study? ↗
Six-month data from 40 participants suggest that Revita helps limit weight regain after GLP-1 discontinuation. 
Via Stocktwits
News headline image
Why Did Glucotrack Stock Surge 12% Pre-Market Today? ↗
The company has received patents for its continuous blood glucose monitoring system. 
Via Stocktwits
Topics Intellectual Property
News headline image
INMD Stock Jumped Nearly 13% Today – What’s Powering The Rally? ↗
According to a Calcalist report, the company is set to go private after a $1.1 billion acquisition by a fund. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Why Did Corcept Therapeutics Stock Surge Over 14% Today? ↗
In the ROSELLA trial, patients receiving relacorilant with nab-paclitaxel saw their risk of death drop by about 35% compared with those given the chemotherapy alone. 
Via Stocktwits
This Is My No. 1 Recommended Vanguard ETF to Buy in 2026 ↗
The stars could be aligning for healthcare stocks this year. This Vanguard ETF is a great way to play it. 
Via The Motley Fool
Topics ETFs Economy
News headline image
Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter? ↗
On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
This ETF Is Proof That the Healthcare Rebound Is Real ↗
Via MarketBeat
Topics ETFs
News headline image
TLRY Stock In Focus After Alliance Global Halves Price Target ↗
Alliance Global cut TLRY’s target price to $10 from $20, citing limited visibility into the company’s long-term sales trajectory and cash flow. 
Via Stocktwits
Topics Cannabis
News headline image
Why Did CRMD Stock Crash 28% Today? ↗
CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data. 
Via Stocktwits
News headline image
Why Did MLTX Stock Jump 45% In Pre-Market Today? ↗
The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder. 
Via Stocktwits
News headline image
Hedge Funds Snap Up Eli Lilly, United Healthcare, And More, Putting Healthcare ETFs Back In The Spotlight ↗
With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensive rotation. 
Via Benzinga
Topics ETFs
News headline image
Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies ↗
Neumora said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with Semaglutide. 
Via Stocktwits
News headline image
How Trump's Shutdown Standoff Could Hand Health-Care ETFs A Lifeline ↗
Trump's comments on health-care negotiations with Democrats can put ETFs like XLV, IHF, and XHS back on investors' radar as Washington's shutdown drags on. 
Via Benzinga
Topics ETFs Government
News headline image
The Healthcare Stock Play That Could Make Millennials Rich ↗
This investment may also make baby boomers, and those from Gen X and Gen Z, rich as well. 
Via The Motley Fool
Topics ETFs
News headline image
Trump Admin Targets Medicaid Spending On Immigrants, Threatening Over $12 Billion California Program ↗
The Trump administration is investigating Medicaid spending in California and other Democrat-led states over potential misuse in immigrant healthcare programs. 
Via Benzinga
Topics Government
News headline image
Trump-nominee Susan Monarez Confirmed As CDC Director By Senate ↗
According to a report by Reuters, the Senate voted 51-47 along party lines to confirm the President’s nominee. 
Via Stocktwits
Topics Government Workforce
News headline image
Here's Why Vanguard's Worst-Performing Sector ETF Is a No-Brainer Buy Right Now ↗
Via The Motley Fool
Topics Artificial Intelligence ETFs
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.